ATE242641T1 - Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation - Google Patents

Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation

Info

Publication number
ATE242641T1
ATE242641T1 AT97936413T AT97936413T ATE242641T1 AT E242641 T1 ATE242641 T1 AT E242641T1 AT 97936413 T AT97936413 T AT 97936413T AT 97936413 T AT97936413 T AT 97936413T AT E242641 T1 ATE242641 T1 AT E242641T1
Authority
AT
Austria
Prior art keywords
crh
skin
inhibitors
stress
agent
Prior art date
Application number
AT97936413T
Other languages
English (en)
Inventor
Theoharis C Theoharides
Original Assignee
Kos Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kos Pharma Inc filed Critical Kos Pharma Inc
Application granted granted Critical
Publication of ATE242641T1 publication Critical patent/ATE242641T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97936413T 1996-08-06 1997-08-06 Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation ATE242641T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/689,277 US6020305A (en) 1996-08-06 1996-08-06 Treatment of stress-induced skin disease by corticotropin releasing hormone antagonists and skin mast cell degranulation inhibitors
PCT/US1997/013776 WO1998005354A2 (en) 1996-08-06 1997-08-06 Treatment of stress-induced skin disease by corticotropin releasing hormone antagonists and skin mast cell degranulation inhibitors

Publications (1)

Publication Number Publication Date
ATE242641T1 true ATE242641T1 (de) 2003-06-15

Family

ID=24767751

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97936413T ATE242641T1 (de) 1996-08-06 1997-08-06 Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation

Country Status (7)

Country Link
US (1) US6020305A (de)
EP (1) EP0942749B1 (de)
AT (1) ATE242641T1 (de)
AU (1) AU3908997A (de)
DE (1) DE69722809T2 (de)
ES (1) ES2201315T3 (de)
WO (1) WO1998005354A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080153761A1 (en) * 1998-04-08 2008-06-26 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
US7906153B2 (en) * 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US20050220909A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Composition for protection against superficial vasodilator flush syndrome
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US20040230559A1 (en) * 1999-08-09 2004-11-18 Mark Newman Information processing device and information processing method
US7923043B2 (en) * 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
US9050275B2 (en) * 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
US9176146B2 (en) * 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
MX2020013450A (es) * 2018-06-11 2021-08-11 Univ Florida Materiales y métodos para tratar el cancer y los trastornos relacionados con el estrés.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2639828B1 (fr) * 1988-12-01 1993-11-05 Lvmh Recherche Utilisation du kaempferol et de certains de ses derives pour la preparation d'une composition cosmetique ou pharmaceutique

Also Published As

Publication number Publication date
US6020305A (en) 2000-02-01
AU3908997A (en) 1998-02-25
DE69722809D1 (de) 2003-07-17
DE69722809T2 (de) 2004-05-19
ES2201315T3 (es) 2004-03-16
EP0942749A2 (de) 1999-09-22
EP0942749B1 (de) 2003-06-11
WO1998005354A3 (en) 1998-05-14
WO1998005354A2 (en) 1998-02-12

Similar Documents

Publication Publication Date Title
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
DE69930739D1 (de) Transdermale verwendung von sekretin zur behandlung von autismus
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
DE69332713D1 (de) Verwendung von Histamine-2 Agonisten zur Behandlung sexueller Funktionsstörungen
ATE390142T1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
BR0107565A (pt) Formas de dosagem de benzimidazol substituìdo e método de emprego das mesmas
ATE446751T1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
ATE172971T1 (de) Heterocyclische neurokinin-antagonisten
DE60326370D1 (de) Verwendung von cgrp-antagonisten-verbindungen zur behandlung von psoriasis
IS3284A7 (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
ATE242641T1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
PT684816E (pt) Composicoes antagonistas do receptor da 5-ht2 uteis no tratamento de doencas venosas
DE69733557D1 (de) Endothelin-antagonisten zur behandlung von herzversagen
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
DK1231908T3 (da) Farmaceutisk præparat, der omfatter en NO-donorforbindelse samt anvendelse heraf
AR023464A1 (es) Usos novedosos de la proteina ox2 de mamifero y reactivos relacionados
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
BR0015424A (pt) Análogos de ácido hidroxieicosatetraenóico e, métodos de seu uso em tratamento de distúrbios de olho seco
AR002258A1 (es) Derivados de fenoxipirimidinilo, preparaciones farmaceuticas que los contienen, un procedimiento para su preparacion y su empleo para preparar medicamentos
UA26886C2 (uk) Солі 1,3-діарил-4,5-поліметилеhімідазолію, що виявляють аhальгезуючу активhість
SE0004026D0 (sv) New use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties